Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and HENRY MARK KUERER.
FUNDA MERIC-BERNSTAM
Connection Strength
4.518
HENRY MARK KUERER
  1. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
    View in: PubMed
    Score: 0.115
  2. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
    View in: PubMed
    Score: 0.105
  3. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.103
  4. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93.
    View in: PubMed
    Score: 0.100
  5. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
    View in: PubMed
    Score: 0.099
  6. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011 Apr; 18(4):932-8.
    View in: PubMed
    Score: 0.097
  7. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5.
    View in: PubMed
    Score: 0.094
  8. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47.
    View in: PubMed
    Score: 0.093
  9. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
    View in: PubMed
    Score: 0.092
  10. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9.
    View in: PubMed
    Score: 0.092
  11. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
    View in: PubMed
    Score: 0.092
  12. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
    View in: PubMed
    Score: 0.091
  13. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8.
    View in: PubMed
    Score: 0.090
  14. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66.
    View in: PubMed
    Score: 0.087
  15. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007 Aug 15; 110(4):731-7.
    View in: PubMed
    Score: 0.075
  16. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
    View in: PubMed
    Score: 0.073
  17. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
    View in: PubMed
    Score: 0.071
  18. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3):464-70.
    View in: PubMed
    Score: 0.071
  19. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72.
    View in: PubMed
    Score: 0.069
  20. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006 Mar; 13(3):310-20.
    View in: PubMed
    Score: 0.068
  21. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
    View in: PubMed
    Score: 0.067
  22. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006 Jan; 243(1):96-101.
    View in: PubMed
    Score: 0.067
  23. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005 Aug 15; 104(4):692-9.
    View in: PubMed
    Score: 0.066
  24. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90.
    View in: PubMed
    Score: 0.066
  25. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
    View in: PubMed
    Score: 0.065
  26. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005 Apr; 200(4):516-26.
    View in: PubMed
    Score: 0.064
  27. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
    View in: PubMed
    Score: 0.062
  28. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer. 2004 Oct 01; 101(7):1514-23.
    View in: PubMed
    Score: 0.062
  29. Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60.
    View in: PubMed
    Score: 0.061
  30. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004 Mar 01; 100(5):942-9.
    View in: PubMed
    Score: 0.059
  31. Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer. 2004 Feb 01; 100(3):490-8.
    View in: PubMed
    Score: 0.059
  32. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol. 2004 Feb 01; 22(3):567-8.
    View in: PubMed
    Score: 0.059
  33. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 Feb; 31(2):974-980.
    View in: PubMed
    Score: 0.058
  34. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg. 2003 Oct; 186(4):371-7.
    View in: PubMed
    Score: 0.058
  35. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
    View in: PubMed
    Score: 0.057
  36. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
    View in: PubMed
    Score: 0.057
  37. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg. 2003 Mar; 196(3):354-64.
    View in: PubMed
    Score: 0.055
  38. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
    View in: PubMed
    Score: 0.055
  39. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002 Jul; 9(6):543-9.
    View in: PubMed
    Score: 0.053
  40. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002 Apr; 9(3):256-65.
    View in: PubMed
    Score: 0.052
  41. Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ. 2002 Mar 09; 324(7337):577-81.
    View in: PubMed
    Score: 0.052
  42. Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J. 2002 Mar-Apr; 8(2):177-80.
    View in: PubMed
    Score: 0.052
  43. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
    View in: PubMed
    Score: 0.049
  44. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.047
  45. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
    View in: PubMed
    Score: 0.047
  46. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol. 2019 Mar; 26(3):815-820.
    View in: PubMed
    Score: 0.041
  47. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
    View in: PubMed
    Score: 0.036
  48. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol. 2014 Oct; 18(5):266-70.
    View in: PubMed
    Score: 0.030
  49. Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
    View in: PubMed
    Score: 0.030
  50. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
    View in: PubMed
    Score: 0.028
  51. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
    View in: PubMed
    Score: 0.028
  52. Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013 Jun; 20(6):1893-9.
    View in: PubMed
    Score: 0.027
  53. Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy. Ann Surg Oncol. 2013 May; 20(5):1514-21.
    View in: PubMed
    Score: 0.027
  54. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13.
    View in: PubMed
    Score: 0.027
  55. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.027
  56. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
    View in: PubMed
    Score: 0.026
  57. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6.
    View in: PubMed
    Score: 0.026
  58. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7.
    View in: PubMed
    Score: 0.026
  59. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012 Jan; 255(1):109-15.
    View in: PubMed
    Score: 0.026
  60. Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44.
    View in: PubMed
    Score: 0.025
  61. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.025
  62. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22.
    View in: PubMed
    Score: 0.025
  63. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
    View in: PubMed
    Score: 0.025
  64. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
    View in: PubMed
    Score: 0.024
  65. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011 Mar 01; 117(5):916-24.
    View in: PubMed
    Score: 0.023
  66. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51.
    View in: PubMed
    Score: 0.023
  67. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8.
    View in: PubMed
    Score: 0.023
  68. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 2010 Jun 15; 116(12):2878-83.
    View in: PubMed
    Score: 0.023
  69. False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. Breast J. 2009 Nov-Dec; 15(6):645-8.
    View in: PubMed
    Score: 0.022
  70. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009 Nov; 198(5):720-5.
    View in: PubMed
    Score: 0.021
  71. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009 Sep; 198(3):387-91.
    View in: PubMed
    Score: 0.021
  72. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62.
    View in: PubMed
    Score: 0.021
  73. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71.
    View in: PubMed
    Score: 0.021
  74. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.
    View in: PubMed
    Score: 0.021
  75. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
    View in: PubMed
    Score: 0.020
  76. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008 Jul 01; 113(1):30-7.
    View in: PubMed
    Score: 0.020
  77. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7.
    View in: PubMed
    Score: 0.020
  78. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007 Dec 01; 110(11):2542-50.
    View in: PubMed
    Score: 0.019
  79. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
    View in: PubMed
    Score: 0.019
  80. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15; 110(4):723-30.
    View in: PubMed
    Score: 0.019
  81. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007 Apr 01; 109(7):1255-63.
    View in: PubMed
    Score: 0.018
  82. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7.
    View in: PubMed
    Score: 0.018
  83. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg. 2006 Oct; 192(4):541-4.
    View in: PubMed
    Score: 0.018
  84. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006 Oct; 192(4):552-5.
    View in: PubMed
    Score: 0.018
  85. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9.
    View in: PubMed
    Score: 0.018
  86. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct; 203(4):475-80.
    View in: PubMed
    Score: 0.018
  87. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006 Jun; 13(6):776-82.
    View in: PubMed
    Score: 0.017
  88. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64.
    View in: PubMed
    Score: 0.017
  89. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg. 2005 Oct; 190(4):598-601.
    View in: PubMed
    Score: 0.017
  90. Determinants of mastectomy in breast conservation therapy candidates. Am J Surg. 2005 Oct; 190(4):602-5.
    View in: PubMed
    Score: 0.017
  91. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.016
  92. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer. 2005 Apr 01; 103(7):1323-9.
    View in: PubMed
    Score: 0.016
  93. Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol. 2005 May; 12(5):391-7.
    View in: PubMed
    Score: 0.016
  94. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
    View in: PubMed
    Score: 0.016
  95. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med. 2005 Jan; 30(1):11-5.
    View in: PubMed
    Score: 0.016
  96. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer. 2004 Sep 15; 101(6):1330-7.
    View in: PubMed
    Score: 0.015
  97. Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer. 2004 Aug 01; 101(3):508-17.
    View in: PubMed
    Score: 0.015
  98. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
    View in: PubMed
    Score: 0.015
  99. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
    View in: PubMed
    Score: 0.015
  100. Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30.
    View in: PubMed
    Score: 0.015
  101. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003 Apr; 10(3):248-54.
    View in: PubMed
    Score: 0.014
  102. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
  103. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
    View in: PubMed
    Score: 0.014
  104. Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002 Nov; 9(9):912-9.
    View in: PubMed
    Score: 0.014
  105. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002 Oct; 184(4):364-8.
    View in: PubMed
    Score: 0.013
  106. Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol. 2001 Dec; 8(10):821-7.
    View in: PubMed
    Score: 0.013
  107. Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer. 2001 Sep 01; 92(5):1092-100.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.